Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Catalyst Pharmaceuticals excels in 2022, eyes sustained growth in epilepsy market

Catalyst Pharmaceuticals delivered exceptional financial performance in 2022, with strong revenue growth and strategic acquisitions positioning the company for continued success.
While facing challenges in maintaining sequential quarterly revenue growth, Catalyst's focus on innovation, patient care, and financial stability presents opportunities for sustained growth.
Overall, Catalyst's industry leadership, financial strength, and commitment to expanding product access and market presence underscore its potential for future growth and success.

Catalyst Pharmaceuticals reports record Q1 earnings, eyes growth opportunities

Catalyst Pharmaceuticals delivered exceptional financial results in Q1 2023, with strong revenue growth and a healthy cash position, positioning the company for continued success.
While facing challenges such as seasonal sales trends and diagnosis rates, the company's strategic focus on acquisitions and market expansion presents promising opportunities for future growth.
With a clear commitment to organic growth, product integration, and market penetration, Catalyst Pharmaceuticals remains poised for sustained performance and market leadership.

Catalyst Pharmaceuticals excels in Q2, eyes global expansion and new treatments

Catalyst Pharmaceuticals delivered strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
While facing challenges in patient identification and treatment, the company remains focused on expansion and innovation in rare disease therapeutics.
Opportunities lie in upcoming product launches, global expansion, and collaboration efforts to drive future growth and market penetration.

Catalyst Pharmaceuticals (CPRX) excels in Q3, eyes global expansion

Catalyst Pharmaceuticals (CPRX) demonstrated robust financial performance in Q3 2023, driven by strong product revenues and strategic initiatives.
While facing challenges in managing launch expenses and regulatory processes, CPRX remains focused on leveraging growth opportunities through global expansion and portfolio enhancements.
With a new CEO appointment and a clear focus on market expansion and innovation, CPRX is poised for sustained growth and value creation in the pharmaceutical sector.

Catalyst Pharmaceuticals posts record revenues, eyes growth in rare diseases

Catalyst Pharmaceuticals delivered strong financial performance in 2023, driven by record revenues and strategic acquisitions.
While facing challenges with FYCOMPA's growth and upcoming patent expiry, the company remains well-positioned for growth in rare disease markets.
Opportunities lie in the launch of AGAMREE, expansion into new therapeutic areas, and leveraging the stickiness of epilepsy drugs post-patent expiry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Catalyst will participate in the upcoming 11th Annual Epilepsy Awareness Day & Education Expo, taking place at the Disneyland Hotel in Anaheim, CA, October 30-31, 2023, to raise awareness and education with the epilepsy community. This event is jointly organized by Sofie's Journey and Epilepsy Alliance of America and is the largest gathering of patients, families, and physicians in the U.S.

Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo

AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older

Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

The Company to Host a Conference Call and Webcast on November 9, 2023, at 8:30 AM ET The Company to Host a Conference Call and Webcast on November 9, 2023, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023

Patrick J. McEnany to Retire as CEO and will Continue to Serve as Catalyst's Chairman Patrick J. McEnany to Retire as CEO and will Continue to Serve as Catalyst's Chairman

Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

ImmunoGen

Inari Medical

Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.

3 Solid Stocks to Buy for Superb Earnings Acceleration

The FDA accepts Catalyst's (CPRX) sNDA to increase the indicated maximum daily dosage of Firdapse 10 mg from 80mg to 100mg for treating Lambert-Eaton myasthenic syndrome. The decision is due on Jun 4, 2024.

Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse

CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today announced that Patrick J. McEnany, Founder, Chairman and CEO of Catalyst, has been bestowed the 2023 Lifetime Achievement Award by BioFlorida at their Annual Meeting last Friday. This prestigious award highlights Mr. McEnany's outstanding accomplishments, unwavering commitment to rare disease patients, dedication to Catalyst's employees, and pivotal role in fostering the growth of Florida's biopharmaceutical ecosystem.

Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida

The sNDA Seeks to Increase the Indicated Maximum Daily Dose for FIRDAPSE to 100mg for the Treatment of Lambert-Eaton Myasthenic Syndrome

Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®

PBF Energy

Praxis Precision Medicines

PBF, PRAX and CPRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 11, 2023.

Best Momentum Stocks to Buy for October 11th

Kyndryl Holdings

Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.

4 Stocks That Exhibit Solid Earnings Acceleration

CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the Catalyst's senior management team, will participate in the 2023 Cantor Global Healthcare Conference which will be held on September 26-28, 2023.

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST / 13:30 BST / 08:30 EDT.

Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update

Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer

Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

CORAL GABLES, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that multiple abstracts highlighting FYCOMPA® (perampanel) CIII will be presented at the upcoming 35th International Epilepsy Congress (“IEC”) taking place on September 2 – 6, 2023 in Dublin, Ireland. These are presentations by Eisai Co., Ltd. ("Eisai"), which holds the rights to FYCOMPA in countries and regions outside the U.S. Some abstracts will also be considered for publication in Epilepsia following the IEC.

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

Catalyst (CPRX) reports better-than-expected second-quarter 2023 results. Management raises full-year 2023 guidance.

Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2023 Earnings Conference Call August 10, 2023 8:30 AM ET Company Participants Alicia Grande - Vice President, Chief Financial Officer and Treasurer Patrick McEnany - Chairman and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Joe Catanzaro - Piper Sandler Les Sulewski - Truist Securities Charles Duncan - Cantor Fitzgerald Operator Hello, and welcome to the Catalyst Pharmaceutical Second Quarter 2023 Financial Results Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation.

Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2023 Earnings Call Transcript

Achieved Record Q2 2023 Total Net Revenues of $99.6 Million Achieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOY Achieved 2023 Second Quarter GAAP EPS Diluted of $0.33 Compared to $0.20 for Q2 2022 Achieved 2023 Second Quarter Non-GAAP EPS Diluted of $0.53 Compared to  $0.28 for Q2 2022 During Q3-23 Completed the Acquisition of the North American License for Vamorolone Submitted sNDA for FIRDAPSE Seeking to Increase the Maximum Indicated Dose to 100 mg per Day Completed the Integration of our FYCOMPA® Commercial and MSL Teams Raising Full Year 2023 Total Revenue Guidance of Between $380 Million and $390 Million Conference Call and Webcast to be Held on August 10, 2023, at 8:30 AM ET

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

ACM Research

Gray TV

Harmony Biosciences Holdings

International Money Express Inc.

Patrick Industries

Titan Machinery

Inherently, investors gravitate toward strong buy value stocks, in much the same way that audience members of a horror film might grip their armrests. As humans, we're basically hardwired – especially in the modern age – to respond positively to discounts.

7 ‘Strong Buy' Value Stocks You Should Be Loading Up On Now

Mr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search CORAL GABLES, Fla., July 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced that Patrick J.

Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End

The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023

Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, July  19 , 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of the exclusive license agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) , announced on June   20 , 2023 [1].

Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone

The company reported record revenues of $85.4 million in 1Q 2023, a 98% YoY increase, and expects its 2Q, 3Q, and 4Q 2023 revenues to be higher than in 1Q. The company estimates about 10% of the patients that are taking 80 mg of FIRDAPSE per day may increase their doses to 100 mg after FDA's approval. It can happen in 3Q 2023, increasing CPRX's quarterly and annual revenues by $3.5 million and $14 million, respectively.

Catalyst Pharmaceuticals: Expecting Higher FIRDAPSE Revenues In A Year

This is a follow-up to my previous concerns about Catalyst Pharmaceuticals' over-dependence on FIRDAPSE, as expressed in my April 2023 article. I previously discussed Catalyst's acquisition of FYCOMPA in December 2022. The current article will revisit my thesis and discuss recent developments, including Catalyst's Q1 2023 performance.

News for Catalyst Pharmaceuticals Stock (CPRX)